Related Experiment Video
Updated: Feb 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer
Rayna Rosati1, Lisa Polin1, Charles Ducker2
1Department of Oncology, Wayne State University School of Medicine and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
Purpose:
Testosterone suppression in prostate cancer is limited by serious side effects and resistance via restoration of androgen receptor (AR) functionality. ELK1 is required for AR-dependent growth in various hormone-dependent and castration-resistant prostate cancer models. The amino-terminal domain of AR docks at two sites on ELK1 to coactivate essential growth genes. This study explores the ability of small molecules to disrupt the ELK1-AR interaction in the spectrum of prostate cancer, inhibiting AR activity in a manner that would predict functional tumor selectivity.
Experimental Design:
Small-molecule drug discovery and extensive biological characterization of a lead compound.
Results:
We have discovered a lead molecule (KCI807) that selectively disrupts ELK1-dependent promoter activation by wild-type and variant ARs without interfering with ELK1 activation by ERK. KCI807 has an obligatory flavone scaffold and functional hydroxyl groups on C5 and C3'. KCI807 binds to AR, blocking ELK1 binding, and selectively blocks recruitment of AR to chromatin by ELK1. KCI807 primarily affects a subset of AR target growth genes selectively suppressing AR-dependent growth of prostate cancer cell lines with a better inhibitory profile than enzalutamide. KCI807 also inhibits in vivo growth of castration/enzalutamide-resistant cell line-derived and patient-derived tumor xenografts. In the rodent model, KCI807 has a plasma half-life of 6 hours, and maintenance of its antitumor effect is limited by self-induced metabolism at its 3'-hydroxyl.
Conclusions:
The results offer a mechanism-based therapeutic paradigm for disrupting the AR growth-promoting axis in the spectrum of prostate tumors while reducing global suppression of testosterone actions. KCI807 offers a good lead molecule for drug development.
Insights
Researchers identified a new molecule, KCI807, that disrupts the interaction between androgen receptor (AR) and ELK1, inhibiting prostate cancer growth. This targeted approach offers a promising therapeutic strategy with fewer side effects than current treatments.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Prostate cancer treatment faces challenges with side effects and resistance due to androgen receptor (AR) functionality.
- ELK1 is crucial for AR-dependent growth in various prostate cancer models, including hormone-dependent and castration-resistant types.
- The amino-terminal domain of AR interacts with ELK1 to coactivate essential growth genes.
Purpose of the Study:
- To explore small molecules that disrupt the ELK1-AR interaction in prostate cancer.
- To inhibit AR activity selectively, predicting functional tumor selectivity.
- To develop a novel therapeutic strategy for prostate cancer treatment.
Main Methods:
- Small-molecule drug discovery and lead compound characterization.
- Biological assays to assess the disruption of ELK1-AR interaction.
- In vitro and in vivo studies using prostate cancer cell lines and xenografts.
Main Results:
- A lead molecule, KCI807, was discovered that selectively disrupts ELK1-dependent promoter activation by wild-type and variant ARs.
- KCI807 binds to AR, blocks ELK1 binding, and inhibits AR recruitment to chromatin by ELK1.
- KCI807 selectively suppresses AR-dependent growth of prostate cancer cells and inhibits tumor xenograft growth, outperforming enzalutamide in some aspects.
Conclusions:
- KCI807 represents a promising lead molecule for drug development in prostate cancer.
- The study offers a mechanism-based therapeutic paradigm for disrupting the AR growth-promoting axis.
- This approach aims to reduce global suppression of testosterone actions while targeting prostate tumors effectively.
Related Concept Videos
Internal Receptors
The Electromagnetic Spectrum
The Electromagnetic Spectrum
IR Spectrum
Transmittance is defined as the ratio of the radiant power passing through a sample to that from the radiation's source. Multiplying the transmittance by 100 gives the percent transmittance (%T), which varies between 100% (no absorption) and 0%...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Mass Spectrum

